Top 10 Biotech Angel Investors in Oceania in January 2026

Last updated: Jan 2026 A list of 10 angel investors that invest in Biotech startups based in Oceania. We rank investors based on the number of investments they made in Biotech companies from Oceania. We update this investor list every month.

Top 10 Biotech Angel Investors in Oceania in January 2026

Investor	Biotech Oceania investments
Mike Wallas	2
Allan Moss	2
David Ross	1
Marko Bogoievski	1
Serge van Dam	1
Catherine Lacavera	1
Paul Davidson	1
Daniel Petre	1
Latesha Randall	1
Melanie Melanie	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Mike Wallas - Advisory Board @ Optifire Pty Ltd

Investment focus

Video, Water, Biotechnology
Seed, Funding Round
Australia

Portfolio highlights

PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
Clipchamp — Create videos with royalty-free music and stock footage, use a pre-made video template, and export in up to 4K video resolution. Get started in-browser, download the Windows app, or create on the go with iOS app.

Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.

Investment focus

Health Care, Medical Device, Biotechnology
Funding Round, Series A, Seed
Australia, United States, The Netherlands

Portfolio highlights

Skykraft — Skykraft is an Australian space services firm that specializes in smallsat constellation design, production, and operation.
Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.

David Ross

Investment focus

Biopharma, Biotechnology
Seed
New Zealand

Portfolio highlights

Helico — Helico is developing a proprietary computational platform for synthetic biology research using modelling tools and AI-based prediction algorithms. The long-term aim is to develop a seed bank of different drugs able to be licensed to grow medical supplies in confined greenhouses anywhere in the world.

Marko retired as CEO of Morrison & Co in 2021 after 13 years of leading the business. He continues to provide guidance for investments in telecommunications and digital infrastructure. His 30 year career has been in the infrastructure and technology sectors in a variety of senior finance, operational and sales roles in the United States and NewZealand. Prior to joining Morrison & Co in 2008, Marko was CFO of Telecom NZ, responsible for corporate finance, M&A and group strategy. Marko is Chair of Vodafone New Zealand.

Investment focus

Biotechnology, Manufacturing
Funding Round
New Zealand

Portfolio highlights

Pictor — PictorDx offers a flexible multiplex proteomics platform that delivers multiple biomarker insights simultaneously and cost-effectively for multiple sample types

Serge has a depth of experience in technology startups that is difficult to rival. As CMO of M-Com, Serge led the growth of M-Com from a four person mobile commerce development company to the world's most successful provider of mobile banking and payment solutions (in both licensed and SaaS categories). He has since held executive levelpositions and Directorships, including as Chair on four boards, of many successful B2B SaaS companies. He is also an avid investor.

Investment focus

Biotechnology, Product Research
Seed
New Zealand

Portfolio highlights

Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand

Catherine Lacavera is the Chief Legal Officer of ShipBob. She previously worked at Color Health as a Chief Legal Officer. Catherine Lacavera attended the University of Toronto.

Investment focus

Medical, Health Care, Biotechnology
Seed, Pre-Seed
Canada, Australia

Portfolio highlights

Skritswap — skritswap has AI technology that enables anyone to understand anything regardless of complexity.
HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.

Paul Davidson joined private equity group, West Coast Capital in 2005 following a successful career in corporate law in the UK, the US and Commonwealth of Independent States. As an active partner in West Coast Capital as well as providing legal counsel, Paul focusses on deal sourcing and transacting.Since joining the group, Paul has successfulyled the acquisition and delisting from the LSE of the UK's largest garden centre business, Wyevale as well as a series of acquisitions and disposals.Prior to joining West Coast Capital headed the corporate team of UK lawyers, McGrigors.In late 1994 Paul was seconded to an oil and gas company called JKX whose focus was on the former Soviet Union, primarily in Ukraine, Georgia and the Russian Federation. JKX listed on the London Stock Exchange in mid 1995 and at that time Paul joined the company as its Legal Director on a full time basis. During his time as Legal Director, Paul gained wide commercial experience as the company concluded a number of transactions throughout the former Soviet Union.